John Spencer was named Chief Financial Officer of Oragenics Inc, effective July 1, 2026. As of November 6, 2026, Oragenics Inc has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on July 6, 2026, naming 1 appointment (Form 8-K, July 6, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Oragenics Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Oragenics Inc reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-07-06. It names 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as Oragenics Inc files it.
Also on the record for Oragenics Inc
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| January 21, 2026 | Stake report, Schedule 13G, by SABBY MANAGEMENT, LLC | 9.9% of the class | 5%+ stakes | Source |
| July 2, 2025 | Stake report, Schedule 13G, by Five Narrow Lane LP | 9.99% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Oragenics Inc now and the warning signs.
Free to see. No signup.
Keep reading
More on Oragenics Inc and the records around it.
Oragenics Inc elsewhere on the record
Companies that share a holder
- Five Narrow Lane LP also filed stake reports on 4 other companies: Expion Energy, Inc. (Aug 2026), BLACKBOXSTOCKS INC. (Apr 2026), INVO FERTILITY, INC. (Jan 2026)
- SABBY MANAGEMENT, LLC also filed stake reports on 15 other companies: Globavend Holdings Ltd (Jan 2026), Jiuzi Holdings, Inc. (Jan 2026), Tempest Therapeutics, Inc. (Jan 2026)
Watch Oragenics Inc
Get an email when Oragenics Inc files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Oragenics Inc?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Oragenics Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Oragenics Inc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
3 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-07-06 | In | Chief Financial Officer | 2026-07-01 | 8-K, 2026-07-06 |
Who leads Oragenics Inc, as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Financial Officer: John Spencer, appointed, effective 2026-07-01 (filed 2026-07-06).
New leaders reset buying decisions — get the Full Report on Oragenics Inc: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Financial Officer at Oragenics Inc, with the record behind each one.
Find candidates like Chief Financial Officer at Oragenics IncEvery change, in the filing's words
Appointed: John Spencer, Chief Financial Officer, effective 2026-07-01
Effective July 1, 2026, the Board appointed John Spencer, the Company's Senior Controller, to serve as the Company's Chief Financial Officer.
- In connection with the appointment of Mr. Spencer as the Company's Chief Financial Officer, Mr. Spencer received an option award equal to $25,000, with an exercise price equal to the closing price of the Company's common stock on the NYSE American immediately prior to the date of the grant.
- Mr. Spencer, age 32, joined the Company in April 2025 as Senior Controller and has led the Company's finance and accounting organization, including SEC reporting, financial planning and analysis, treasury, budgeting, internal controls, audit coordination, and capital markets support.
- From March 2022 through April 2025, Mr. Spencer operated a fractional chief financial officer and financial consulting practice, providing financial leadership to publicly traded and privately held companies across multiple industries, including healthcare, sports and entertainment, and professional services.
- His responsibilities included SEC reporting, financial planning and analysis, budgeting and forecasting, treasury, internal controls, acquisition accounting, capital planning, operational finance, and strategic financial leadership.
Tools for this story
Each opens in a new tab, filled in for Oragenics Inc. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.